Results 311 to 320 of about 1,127,554 (354)

Survivorship after neoadjuvant chemotherapy

The Lancet Oncology, 2022
Jin, Zhang, Chaoyang, Liang, Wenquan, Niu   +2 more
openaire   +2 more sources

Neoadjuvant chemotherapy for cervical cancer

Expert Opinion on Pharmacotherapy, 2003
None of the current surgical or radiation treatment strategies for cervical cancer satisfactorily leads to a high disease-free survival and a low risk for treatment-related complications in patients with bulky or locally-advanced disease. Neoadjuvant chemotherapy (NACT) prior to surgery or radiation therapy has been studied as a means to reduce tumour ...
openaire   +2 more sources

Neoadjuvant Chemotherapy and Biomarkers

2020
Neoadjuvant or presurgical therapy refers to the administration of therapy before surgery and has been used for over two decades to downstage locally advanced and unresectable primary breast cancers to make them operable. The goal of neoadjuvant therapy is to improve surgical outcomes by causing tumor shrinkage by providing effective systemic therapy ...
Niketa Chotai, Supriya Kulkarni
openaire   +1 more source

Neoadjuvant Chemotherapy

Breast Disease, 2004
Marjorie C, Green, Francisco J, Esteva, Gabriel N, Hortobagyi   +2 more
openaire   +2 more sources

Neoadjuvant Chemotherapy

2021
Brandon Bernard, Thomas W. Flaig
openaire   +1 more source

Neoadjuvant chemotherapy for ovarian cancer.

Oncology (Williston Park, N.Y.), 2005
Primary debulking surgery by a gynecologic oncologist remains the standard of care in advanced ovarian cancer. Optimal debulking surgery should be defined as no residual tumor load. In retrospective analyses, neoadjuvant chemotherapy followed by interval debulking surgery does not seem to worsen prognosis compared to primary debulking surgery followed ...
Vergote, Ignace, van Gorp, Toon, Amant, Frederic, Neven, Patrick, Berteloot, Patrick   +4 more
openaire   +2 more sources

Neoadjuvant Chemotherapy

Nihon rinsho. Japanese journal of clinical medicine, 2013
Filip T. Troicki, Filip T. Troicki, Filip T. Troicki, Carlos A. Perez, Wade L. Thorstad, Brandon J. Fisher, Larry C. Daugherty, Filip T. Troicki, Jaganmohan Poli, Larry C. Daugherty, Brandon J. Fisher, Johannes Classen, Brandon J. Fisher, Larry C. Daugherty, Larry C. Daugherty, Brandon J. Fisher, John P. Lamond, George E. Laramore, Jay J. Liao, Jason K. Rockhill, Jay J. Liao, George E. Laramore, Jason K. Rockhill, Lindsay G. Jensen, Brent S. Rose, Arno J. Mundt, George E. Laramore, Jay J. Liao, Jason K. Rockhill, Brandon J. Fisher, Larry C. Daugherty, Yan Yu, Laura Doyle, Theodore E. Yaeger, Susan M. Varnum, Marianne B. Sowa, William F. Morgan, James H. Brashears, Darek Michalski, M. Saiful Huq, Brian F. Hasson, Theodore E. Yaeger, Luther W. Brady, Cherie Yaeger, John P. Christodouleas, Edward J. Gracely   +45 more
openaire   +3 more sources

Neoadjuvant induction chemotherapy.

Minerva ginecologica, 2006
Neoadjuvant chemotherapy (NACT) and neoadjuvant hormonal therapy (NAHT) have been adopted worldwide as appropriate, if not standard of care, options of treatment for patients with locally advanced carcinoma of the breast. The initial role of NACT was the conversion of so called inoperable tumors into those for which mastectomy could now be performed ...
openaire   +1 more source

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline

Annals of Surgical Oncology, 2022
N. Tamirisa, K. Hunt
semanticscholar   +1 more source

Breakthrough for neoadjuvant chemotherapy

Breast Cancer, 2007
Primary breast cancer is considered today as a systemic disease with a locoregional component. Systemic treatment is therefore, considered as a fundamental component of the medical management of patients suffering from this endemic malignancy. Postoperative application of chemo-, endocrine or immunological therapies are always lacking the control of ...
openaire   +1 more source